Why Viking Therapeutics Stock Popped Nearly 4% Today The company's obesity drug could have more potential than originally believed.
Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity? The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years.
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test.
Viking Therapeutics: What's Next? Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts These companies aren't performing as badly as their stock-market performances this year suggest.
Benzinga Bulls And Bears: Sunrun, Newegg, Walmart — And Powell Offers Rate Cut Hope Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Here's Why Shares in Viking Therapeutics Crashed This Week The phase 2 trial results for its key drug didn't pan out quite as planned.
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? A disappointing result for its oral obesity candidate hammered the stock price.
Here's Why Viking Therapeutics Bounced Back Today Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (
NYSE: PLTR ) and Viking Therapeutics (
NASDAQ: VKTX ), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior.
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns San Diego, CA – Viking Therapeutics (
NASDAQ: VKTX ) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,
Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27.
Which stocks are experiencing notable movement on Tuesday? Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive.
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday? Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally.
These stocks are moving in today's session Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
